Table 1.
Diagnostic instruments comparison table
| DSM-IV Checklist1 | SDSS | SCID1 | DIS-IV1 | CIDI-21 | |
|---|---|---|---|---|---|
| Full Name | Diagnostic Statistical Manual-IV Checklist | Substance Dependence Severity Scale |
Structured Clinical Interview for DSM-IV |
Diagnostic Interview Schedule-IV | Composite International Diagnostic Interview-2 |
| Diagnostic Instrument Characteristics | |||||
| Provides SUD Diagnosis by DSM-IV criteria | X | X | X | X | |
| Assesses Lifetime SUD Symptoms | X | X | X | ||
| Assesses Past 30 day SUD Symptoms | X | X | X | X | X |
| Provides SUD Severity Index | X | X | |||
| Assesses SUD remission2 | X | X | X | ||
| Assesses Onset of Symptoms | X | X | X | ||
| Measures Frequency of Drug Use | X | X | |||
| Measures Amount of Drug Use | X | X | |||
| Psychometric Properties3 | |||||
| Reliability studies | X | X | X | X | X |
| Validity studies | X | X | X | X | X |
| Valid as SUD Treatment Outcome Measure | X | ||||
| Instrument Administration | |||||
| Time to Administer (minutes) | 10–15 | 30–45 | 20–30 | 15–25 | 20–30 |
| Interviewers with clinical background preferred | X | X | |||
| Challenge to Administerr4 | X | XX | XX | X | X |
| Public acceptability | |||||
| Prior use in published clinical trials | X | X | X | ||
| Prior use in published epidemiological studies | X | X | |||
| Accepted in first-tier journal publications | X | X | X | X | |
| Prior use by CTPs | |||||
| Automatization | |||||
| Computer data entry available | X | X | X | X | X |
| Computer scoring available | X | X | X | X | X |
| Computerized clinical summary | X | ||||
| Training considerations | |||||
| 2–3 days of training required | X | X | X | X | X |
| Training supervision requirements5 | X | XX | XX | X | X |
| Financial Considerations | |||||
| Proprietary Fees | X6 | X7 | X8 | ||
| International Considerations | |||||
| Provides SUD diagnosis by ICD-10 criteria | X | X | |||
| Translated into other languages | X | X | X | ||
Only the substance use sections of these instruments were included in this review.
Partial or full remission, early or sustained remission, with or without physiological dependence, on agonist therapy in a controlled environment.
There are no peer-reviewed articles comparing the relative reliability/validity of these five instruments; this table only notes whether reliability/validity studies have been published.
This row presents the reviewers assessment of the challenge of administering these instruments for interviewers. X = light to moderate challenge to administer; XX = moderate-to-heavy challenge to administer.
This row presents the reviewers assessment of the training supervision requirements for new interviewers using these instruments. X = light to moderate supervisory requirements; XX = moderate-to-heavy supervisory requirements.
$50 for unlimited use.
$2,000 per project or $15,000 for unlimited use.
$500 per project.